Age Related Macular Degeneration News and Research

RSS

Research reveals link between proteins causing Alzheimer's disease and age-related sight loss

Newly published research has revealed a close link between proteins associated with Alzheimer's disease and age-related sight loss.

10 Mar 2021

Phase 2 clinical trial is now open at Columbia to test gene therapy for dry macular degeneration

A phase 2 clinical trial is underway at Columbia University and NewYork-Presbyterian to test an investigational gene therapy for dry age-related macular degeneration, a progressive, chronic eye disease with no cure and a leading cause of blindness in the United States.

9 Mar 2021

Scientists find new therapeutic approach to effectively treat age-related macular degeneration

Runt-related transcription factor 1 (RUNX1) has been linked to retinal neovascularization and the development of abnormal blood vessels, which result in vision loss in diabetic retinopathy.

22 Feb 2021

New method can help evaluate potential sight-preserving properties

Scientists like the John A. Moran Eye Center's Paul S. Bernstein, MD, PhD, know a special class of lipids, or fatty acids, found in the retina of the eye and in just a few other parts of the body play an important role in maintaining vision.

5 Feb 2021

Pioneering new eye test may predict wet AMD three years before symptoms develop

A pioneering new eye test, developed by scientists at UCL in collaboration with the Western Eye Hospital, London, may predict wet AMD, a leading cause of severe sight loss, three years before symptoms develop.

18 Dec 2020

Researchers develop first biohybrid artificial retina with silk fibroin and retinal cells

An international research led by the Complutense University of Madrid has taken a further step to solve the age-related macular degeneration (AMD)-derived blidness problem with the development of the first biohybrid artificial retina built with silk fibroin and retinal cells.

11 Dec 2020

Research reveals insights into potential drivers of 'wet' age-related macular degeneration

"Wet" age-related macular degeneration (AMD) is one of the most common causes of irreversible vision loss in the elderly, and it occurs when abnormal and leaky blood vessels form in the retina, in part due to inflammation.

11 Dec 2020

RetinAI collaborates with Novartis to provide AI solutions for ophthalmology projects

RetinAI Medical AG announces a multi-year collaboration with Novartis Pharma AG under which RetinAI’s IT solutions and artificial intelligence tools shall be employed to support multiple projects in ophthalmology and digital health. Both companies have previously worked successfully on pilot projects in this disease area.

10 Dec 2020

Study: Global public health services fail to meet targets to reduce avoidable sight loss

A new global study has found no significant reduction in the number of people with treatable sight loss since 2010.

3 Dec 2020

Researchers use new imaging technique to produce digital reconstruction of eye tissues

A new study by scientists at the University of Southampton has made a breakthrough that could help the search for treatments against age related sight loss.

2 Dec 2020

Researchers find way for customized programming of human stem cells

Induced pluripotent stem cells (iPS) have the potential to convert into a wide variety of cell types and tissues for drug testing and cell replacement therapies. However, the "recipes" for this conversion are often complicated and difficult to implement.

30 Nov 2020

An acebuchin-oil-enriched diet helps to reduce arterial blood pressure

An acebuchin-oil-enriched diet helps to reduce arterial blood pressure, as shown by a study carried out by the Cardiovascular Physiopathology research group at the Physiology Department of the University of Seville.

17 Nov 2020

Pioneering stem cell research may help restore sight to people with macular diseases

Eye research charity Fight for Sight has announced funding for a ground-breaking stem cell research study which could reverse sight loss for people with macular diseases such as age-related macular degeneration and juvenile macular dystrophies.

12 Nov 2020

Postdoctoral fellow at LSU Health New Orleans becomes first NIH Outstanding Scholar

Khanh Do, PhD, a postdoctoral fellow at LSU Health New Orleans Neuroscience Center of Excellence, is a member of the first group chosen by the National Institutes of Health (NIH) as NIH Outstanding Scholars in Neuroscience.

11 Nov 2020

Scripps Research scientists uncover potential new strategy for treating eye diseases

Scientists at Scripps Research have uncovered a potential new strategy for treating eye diseases that affect millions of people around the world, often resulting in blindness.

27 Oct 2020

Common medication used to treat diabetic macular edema is less effective in Black patients

A medication frequently used to treat diabetic macular edema, which is the most common cause of blindness in people with diabetes, is less effective when used to treat the condition in Black patients, new study results show.

22 Oct 2020

Newly developed light-sensing protein restores vision in blind mice

A newly developed light-sensing protein called the MCO1 opsin restores vision in blind mice when attached to retina bipolar cells using gene therapy.

22 Oct 2020

Researchers discover a promising treatment for frequent form of blindness in the elderly

Researchers at Ghent University, Belgium, have found a promising treatment for the most frequent form of blindness in the elderly.

13 Oct 2020

Researchers identify a promising method to stop COVID-19 infection

While the world waits eagerly for a safe and effective vaccine to prevent infections from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus behind the COVID-19 pandemic, researchers also are focusing on better understanding how SARS-CoV-2 attacks the body in the search for other means of stopping its devastating impact.

8 Oct 2020

Phase 2 clinical trial to examine the effects of razuprotafib on COVID-19 patients

Researchers at the University of Cincinnati and UC Health will host a Phase 2 clinical trial (NCT04511650) to examine the effects of a drug that targets blood vessel inflammation and injury in patients with COVID-19.

22 Sep 2020